What AI Can (and Can’t) Do in a Phase I Oncology Trial Right Now
A practical guide for sponsors evaluating AI claims in early-phase oncology By the Medelis Team · November 2026 AI comes… [read more]
Read articleYou need the right data, as early as possible, to optimize the results of your oncology drug development efforts. As a specialty oncology CRO, Medelis has the breadth of capabilities, depth of expertise, focus and agility to deliver accurate results – quickly.
For our clients, this means more than completing your trial on time and on budget; it also provides the decision support to determine your next clinical move.






A practical guide for sponsors evaluating AI claims in early-phase oncology By the Medelis Team · November 2026 AI comes… [read more]
Read articleBy Dan Weng, CEO and Brad Phillips, VP of Clinical Operations, Medelis This year’s ASCO theme is “The Science and… [read more]
Read articleAs we kickoff 2026, here are the operational and strategic realities shaping Q1–Q2 2026 oncology starts. Reality #1: Phase I… [read more]
Read article